Ji-Won Kim; Youngil Koh; Dong-Wan Kim; Yong-Oon Ahn; Tae Min Kim; Sae-Won Han; Do-Youn Oh; Se-Hoon Lee; Seock-Ah Im; Tae-You Kim; Dae Seog Heo; Yung-Jue Bang

doi:10.4143/crt.2013.45.4.325

Articles

Page Path: HOME > Cancer Res Treat > Volume 45(4); 2013 > Article

Original Article Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer: Ji-Won Kim, MD^1,2, Youngil Koh, MD, MS^1,2, Dong-Wan Kim, MD, PhD^1,2, Yong-Oon Ahn, PhD², Tae Min Kim, MD, PhD^1,2, Sae-Won Han, MD, PhD^1,2, Do-Youn Oh, MD, PhD^1,2, Se-Hoon Lee, MD, PhD^1,2, Seock-Ah Im, MD, PhD^1,2, Tae-You Kim, MD, PhD^1,2, Dae Seog Heo, MD, PhD^1,2, Yung-Jue Bang, MD, PhD^1,2; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2013;45(4):325-333.
DOI: https://doi.org/10.4143/crt.2013.45.4.325
Published online: December 31, 2013

¹Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

²Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Correspondence: Dong-Wan Kim, MD, PhD. Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.
Tel: 82-2-2072-2995, Fax: 82-2-764-2199, kimdw@snu.ac.kr

*Ji-Won Kim and Youngil Koh contributed equally to this work.

• Received: December 7, 2012 • Accepted: April 7, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

14,033 Views
104 Download
47 Web of Science
40 Crossref
48 Scopus

prev next

Full Article

Download PDF

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
Acknowledgments
NOTES
REFERENCES

Abstract

Purpose
Vascular endothelial growth factor (VEGF)-A, VEGF₁₆₅b, interleukin (IL)-1β, and transforming growth factor (TGF)-β1 are known to influence tumor angiogenesis. Clinical implications of these cytokines need to be elucidated.
Materials and Methods
Using clinical data and baseline serum samples of 140 consecutive patients with advanced non-small cell lung cancer who received platinum-based combination chemotherapy, we investigated the association among serum cytokine levels, treatment outcomes, as well as leukocyte and platelet counts.
Results
The median age of patients was 64 years (range, 26 to 86 years). The male to female ratio was 104:36. High TGF-β1 and IL-1β levels were associated with shorter progression-free survival, and high VEGF-A and IL-1β levels were associated with shorter overall survival in the univariate analysis. VEGF₁₆₅b was not related to the treatment outcomes. Leukocytosis and thrombocytosis were associated with shorter overall survival. The multivariate analysis demonstrated that VEGF-A, IL-1β, and leukocytosis were significant prognostic factors (p=0.0497, p=0.047, and p<0.001, respectively). Leukocytosis was not associated with recent pneumonia (p=0.937) and correlated with VEGF-A (p<0.001) and TGF-β1 (p=0.020) levels.
Conclusion
Serum VEGF-A, TGF-1β, and IL-1β levels, in addition to leukocyte and platelet counts, are shown to be associated with clinical outcomes. Leukocyte and platelet counts are correlated with serum VEGF-A and TGF-β1 levels.
Key words: Vascular endothelial growth factor, Interleukin-1beta, Transforming growth factor beta1, Leukocytes, Blood platelets, Non-small cell lung carcinoma

Introduction

Angiogenesis, a process fundamental to tumor growth, is regulated by angiogenic cytokines, such as vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-β, and interleukin (IL)-1β [1,2].

Previously, a number of studies demonstrated that an elevated level of circulating VEGF-A was associated with tumor aggressiveness and unfavorable survival in patients with non-small cell lung cancer (NSCLC) [3]. In contrast, VEGF₁₆₅b, a splice variant of VEGF, inhibited VEGF-mediated angiogenesis. The expression of VEGF₁₆₅b was associated with slower tumor growth in vivo and benign tissue expressed a higher level of VEGF₁₆₅b than the malignant tissue [4]. However, there has been no report regarding serum VEGF₁₆₅b as a predictive or prognostic factor in patients with cancer.

TGF-β can induce VEGF in the fibroblastic and epithelial cells in vivo and promote angiogenesis [5,6]. In patients with NSCLC, tumor TGF-β1 level was associated with angiogenesis, tumor progression, and prognosis [7]. In addition, TGF-β1 enhanced the lethal effects of DNA-damaging agents in a human lung-cancer cell line [8]. Postoperative plasma TGF-β1 levels in patients with operable breast cancer were significantly higher compared to healthy individuals [9]. Preoperative plasma TGF-β1 levels in patients with advanced breast cancer and prostate cancer are associated with metastasis and disease progression [10,11]. However, the clinical role of serum TGF-β1 level in patients with NSCLC has not yet been well established.

IL-1β, an inflammatory cytokine, was identified as an essential initiating trigger of VEGF-dependent angiogenesis [2]. Serum IL-1β level in patients with ovarian cancer was significantly higher compared with healthy controls, and significantly decreased after surgical intervention [12]. However, clinical implications of serum IL-1β in patients with NSCLC are still uncertain.

On the other hand, VEGF-A and TGF-β1 are stored in and released from leukocytes and platelets, as well as tumor cells [3,7,13-15]. IL-1β is also produced by the peripheral blood mononuclear cells, as well as tumor cells [2,16]. Serum VEGF-A level was correlated with leukocyte or platelet counts of the peripheral blood [17,18]. However, the association between serum TGF-β1 or IL-1β levels and leukocyte or platelet counts in cancer patients has not been studied previously.

In this study, we aim to elucidate clinical implications of these cytokines as predictive or prognostic markers, and to correlate among serum cytokine levels, baseline leukocyte or platelet counts, and treatment outcomes.

Materials and Methods

1. Patient population

Patients with solid tumors, who were planned to receive chemotherapy, were asked to participate in the pharmacogenomic study at Seoul National University Hospital (IRB Registration No. H-0610-020-186). After obtaining informed consent, patients donated blood for research purposes, and were registered in the database. From this database, we selected patients with stage IIIB or IV NSCLC who were treated with platinum-based combination chemotherapy as a first-line treatment between September 2005 and September 2008. Patients with histologically confirmed NSCLC were eligible for this study. Platinum-based combination chemotherapy was defined as cisplatin or carboplatin, plus one of the following: taxane, gemcitabine, vinorelbine, and etoposide. Patients who received concurrent chemoradiation as a first-line treatment or who had any history of prior chemotherapy, including adjuvant therapy, were excluded.

2. Study objectives

The main objective of this study was to evaluate the association between VEGF-A, VEGF₁₆₅b, IL-1β, and TGF-β1 serum levels and treatment outcomes of patients. In addition, the correlation of serum cytokine levels with leukocyte or platelet counts was evaluated. The prognostic impact of leukocyte or platelet counts was also studied.

3. Acquisition of clinical data

Data regarding patient demographics, pathologic classification, treatment response, progression-free survival (PFS), and overall survival (OS) were obtained via a medical record review. We also collected clinical data regarding leukocyte and platelet counts at the time of serum sampling, along with the history of infection requiring antibiotics treatment within 1 month prior to chemotherapy. Patients who had smoked more than 100 cigarettes during the lifetime were defined as smokers. Tumor histology and subtypes were classified by the World Health Organization (WHO) criteria [19]. The treatment response was evaluated using a computed tomography scan by the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.0 [20]. PFS was calculated from the initiation of chemotherapy to documented disease progression or death from any cause. OS was calculated from the start of chemotherapy to death from any cause.

4. Quantification of serum cytokines

Serum samples acquired before chemotherapy were used for this study. The blood samples were collected and allowed to clot before centrifugation. Serum was removed and stored in liquid nitrogen until used. To measure cytokine levels from the baseline serum samples, enzyme-linked immunosorbent assay (ELISA) was performed, using commercially available kits, following the manufacturer's instructions for the following markers: VEGF-A (R&D Systems, Minneapolis, MN), VEGF₁₆₅b (R&D Systems), IL-1β (R&D Systems), and TGF-β1 (R&D Systems). To measure serum levels of latent complexes of TGF-β1, the activation procedure by acidification was performed before ELISA as the manufacturer's instructions.

The capture antibody was diluted to the working concentration in phosphate buffered saline without carrier protein. A 96-well microplate was coated with the diluted capture antibody. The plate was sealed and incubated overnight at room temperature. After incubation, each well was aspirated and washed with wash buffer three times. Each well was then blocked with block buffer and incubated at room temperature for 1 hour. Each well was aspirated and washed again with a wash buffer three times. When the plate was prepared, the samples or standards in an appropriate diluent were added to each well. The plate was covered with an adhesive strip, which was then incubated at room temperature according to the manufacturer's instructions. After incubation, each well was washed with a wash buffer three times. Then, the detection antibody was added to each well. The plate was covered with a new adhesive strip and incubated at room temperature. After incubation, each well was washed again with a wash buffer three times. The working dilution of streptavidin-HRP was added to each well. The plate was covered and incubated again at room temperature, avoiding any direct light. After incubation, each well was washed again with a wash buffer three times. A substrate solution was added to each well. Then, the plate was incubated again at room temperature, avoiding any direct light. After incubation, a stop solution was added to each well. The optical density of each well was determined using a microplate reader (Multiskan Ascent, MTX Lab Systems, Inc., Vienna, VA), which was set to 450 nm with wavelength correction at 540 nm. Using measured optical density values, the concentration of each well was calculated. The samples were assayed in duplicate.

5. Statistical analysis

The median PFS and OS were calculated using the Kaplan-Meier method. The univariate and multivariate analyses of categorical variables was performed using logistic regression. The univariate and multivariate analyses of risk factors for survival data were performed using the Cox proportional hazard model. Variables with a p-value in the univariate analysis of less than 0.05 were selected for the multivariate analysis. Mann-Whitney U test was used to compare two different groups, consisting of non-parametric continuous variables. To correlate between serum cytokine levels and leukocyte counts, the Pearson correlation was used. Two-sided p-values below 0.05 were considered statistically significant. SPSS ver. 17.0 (SPSS Inc., Chicago, IL) software was used for all the statistical analyses.

6. Ethical considerations

Signed informed consents for chemotherapy and blood sample collection for the pharmacogenomic study were obtained from all patients before treatment. The protocol of this study was reviewed and approved by the institutional review board of Seoul National University Hospital (IRB Registration No. H-0906-071-284) and conducted in accordance with the precepts established by Helsinki Declaration.

Results

1. Patient characteristics

A total of 140 patients were enrolled in this study. The median age of patients was 64 years (range, 25 to 86 years). One hundred four patients (74.3%) were male. Ninety patients (64.3%) were previous or current smokers. Tumor histology was as follows: adenocarcinoma in 73 patients (52.1%), squamous cell carcinoma in 29 patients (20.7%), large cell neuroendocrine carcinoma in 4 patients (2.9%), and not otherwise specified cases in 34 patients (24.3%). Twentyfour patients (17.1%) were initially diagnosed with stage IIIB disease. Among the other 116 patients (82.9%) with initial stage IV, 109 patients initially had metastatic disease and 7 patients had recurrent disease after curative treatment. Eastern Cooperative Oncology Group performance status were grade 0 in 11 patients (7.9%), 1 in 107 patients (76.4%), and 2 in 22 patients (15.7%). Chemotherapy regimens were as follows: taxane plus platinum in 98 patients (70.0%), gemcitabine plus platinum in 41 patients (29.3%), and etoposide plus platinum in 1 patient (0.7%).

During a median follow-up of 20.5 months (range, 1.0 to 40.7 months), 125 patients (89.3%) experienced disease progression and 82 patients (58.6%) died. The treatment response could be evaluated in 132 patients. The response rate of platinum-based combination chemotherapy was 47.0%. The median PFS was 3.9 months (95% confidence interval [CI], 3.0 to 4.7 months). The median OS was 13.0 months (95% CI, 9.7 to 16.3 months).

2. Serum cytokine levels and treatment results

The median VEGF-A level was 660 pg/mL (range, 49 to 3,722 pg/mL). VEGF₁₆₅b levels were detectable (>15.6 pg/mL) by ELISA in 17 samples (12.1%). The median TGF-β1 level was 11,180 pg/mL (range, 511 to 41,210 pg/mL). IL-1β levels were detectable (>1.56 pg/mL) by ELISA in 19 samples (13.6%). The associations among serum cytokine levels were not statistically significant (data not shown).

The results of the univariate analysis are shown in Table 1. Smoking history was a significant factor for OS (p=0.020). Histology was a significant factor for the treatment response (p=0.038) and OS (p=0.013). The performance status was a significant factor for PFS (p<0.001) and OS (p=0.001). The association between cytokine levels and treatment responses was not significant. Patients with high VEGF-A levels (≥1,000 pg/mL, n=41) had shorter OS (median, 8.2 months [95% CI, 4.6 to 11.8 months] vs. 13.8 months [95% CI, 8.6 to 19.0 months]; p=0.035). VEGF₁₆₅b was not associated with clinical outcomes of patients. High TGF-β1 levels (≥10,000 pg/mL, n=77) were associated with shorter PFS (median, 3.1 months [95% CI, 2.4 to 3.8 months] vs. 4.9 months [95% CI, 4.0-5.8 months]; p=0.025). High IL-1β levels (≥3.00 pg/mL, n=10) were associated with shorter PFS (median, 3.5 months [95% CI, 1.9 to 5.1 months] vs. 4.2 months [95% CI, 3.2 to 5.3 months]; p=0.046) and OS (median, 7.1 months [95% CI, 4.5 to 9.7 months] vs. 13.5 months [95% CI, 9.9 to 17.1 months]; p=0.030).

The results of the multivariate analysis are shown in Table 2. After adjustment for performance status, which was a significant variable in the univariate analysis, high TGF-β1 and IL-1β levels tended to be associated with a high risk of disease progression with a marginal significance (p=0.075 and p=0.070, respectively). VEGF-A (Fig. 1A) and IL-1β (Fig. 1B) were significant prognostic factors (p=0.0497 and p=0.047, respectively) after adjustment for smoking history, histology, and performance status.

3. Serum cytokine levels and baseline leukocyte or platelet counts

Serum VEGF-A levels were correlated with leukocyte counts (r=0.422, p<0.001) (Fig. 2A) and platelet counts (r=0.462, p<0.001; data not shown). Serum TGF-β1 levels were also correlated with leukocyte counts (r=0.197, p=0.020) (Fig. 2B) and platelet counts (r=0.359, p<0.001; data not shown). However, serum VEGF₁₆₅b and IL-1β levels were associated with neither leukocyte counts (p=0.071 and p=0.378, respectively) nor platelet counts (p=0.495 and p=0.816, respectively).

4. Baseline leukocyte or platelet counts and treatment results

The median leukocyte and platelet counts at the time of treatment were 7,505/mm³ (range, 3,940 to 55,560/mm³) and 278,000/mm³ (range, 68,000 to 692,000/mm³), respectively. The effects of the baseline leukocyte and platelet counts on OS are shown in Table 3. High leukocyte counts (≥9,000/mm³, n=39) and high platelet counts (≥400,000/mm³, n=20) were significant risk factors for OS in the univariate analysis. After adjustment for smoking history, histology, and performance status, the baseline leukocyte count was an unfavorable prognostic indicator (p<0.001) (Fig. 3).

5. History of infection and baseline leukocyte or platelet counts

Nineteen patients (13.6%) required antibiotics treatment for pneumonia within 1 month before the initiation of chemotherapy. No other infectious diseases developed. All patients had recovered from pneumonia, and antibiotics were stopped at the time of treatment. No significant association was found between the history of pneumonia and baseline leukocyte counts (p=0.937). The baseline platelet counts were also not significantly different according to the history of pneumonia (p=0.775).

Discussion

As previously reported [3], serum VEGF-A level was a poor prognostic factor in this study. A previous study demonstrated that high tumor VEGF levels predicted a poor response to chemotherapy in patients with advanced breast cancer [21]. However, in the present study, serum VEGF-A level was associated with neither treatment response nor PFS.

On the other hand, VEGF-A exists as a number of isotypes, resulting from alternative pre-mRNA splicing. While most VEGF isotypes promotes angiogenesis, several anti-angiogenic VEGF isotypes have also been identified. Among them, the most dominant isotype is VEGF₁₆₅b [4,22]. Since there has been no study regarding the predictive or prognostic role of serum VEGF₁₆₅b level in patients with cancer, we focused on the clinical implication of VEGF₁₆₅b in this study. However, we could not find any significant association between serum VEGF₁₆₅b levels and treatment outcomes. Given that serum VEGF₁₆₅b was not detectable by ELISA in most patients, the predictive or prognostic role of serum VEGF₁₆₅b level is still inconclusive, and these associations should be evaluated again in further studies using more accurate quantification methods than ELISA.

Previously, tumor TGF-β1 level was reported to correlate with angiogenesis, tumor progression, and prognosis in patients with NSCLC [7]. In addition, TGF-β1 enhanced the lethal effects of DNA-damaging agents in a human lung-cancer cell line [8]. From these results, we hypothesized that serum TGF-β1 level might be associated with the chemotherapy response and prognosis. The univariate analysis demonstrated that high serum TGF-β1 level was significantly associated with shorter PFS, although this association was not statistically significant in the multivariate analysis. This subject needs to be evaluated again from future studies.

In this study, only 19 out of 140 patients (13.5%) had detectable (>1.56 pg/mL) serum IL-1β levels. Nevertheless, in the univariate analysis, we could find that a subset of patients with serum IL-1β levels higher than 3.00 pg/mL exhibited unfavorable clinical outcomes. This novel finding suggests that serum IL-1β level can be a useful predictive or prognostic marker in patients with advanced NSCLC. However, due to a limitation of the quantification method and marginal significance for PFS in the multivariate analysis, this result needs to be validated in further studies using a more accurate assay method and a larger patient cohort than those we used.

Normally, VEGF-A is stored in and released from leukocytes and platelets [3,13]. Previous studies showed that serum VEGF-A level was correlated with leukocyte or platelet counts of the peripheral blood, as well as tumor volume in patients with NSCLC [17,18]. During the coagulation process, activated platelets release VEGF in a rapid discharge reaction [23,24]. Our results also showed that serum VEGF-A levels were significantly correlated with both leukocyte and platelet counts. Besides VEGF-A, TGF-β1 are stored in and released from leukocytes and platelets [7,14,15]. IL-1β is also reported to be produced by leukocytes [2,16]. However, the association between serum TGF-β1 or IL-1β levels and leukocyte or platelet counts has not been well known. In the present study, serum TGF-β1 levels were significantly correlated with both leukocyte and platelet counts, while serum IL-1β was not.

Since serum VEGF-A level was a significant prognostic factor and significantly related to leukocyte and platelet counts, we evaluated the role of the baseline leukocyte and platelet counts as prognostic factors. Interestingly, leukocytosis and thrombocytosis were significantly associated with shorter OS in the univariate analysis, and the multivariate analysis showed that leukocytosis was an unfavorable prognostic factor. Since many other infectious causes, such as pneumonia, are able to induce leukocytosis, we compared the baseline leukocyte or platelet counts between patients with infection and those without. However, the baseline leukocyte or platelet counts were not significantly different between the two groups. In summary, high serum VEGF-A level was significantly associated with leukocytosis, and both leukocyte count and serum VEGF-A level were significant prognostic factors. In addition, these associations were independent from the previous history of infectious diseases.

A previous study demonstrated that the VEGF content of the isolated peripheral blood mononuclear cells and platelets was higher in cancer patients compared to healthy individuals [13]. In another study, serum VEGF levels were significantly higher than the matched plasma VEGF, and the difference between serum VEGF and plasma VEGF was also significantly higher in cancer patients with normal platelet levels than in normal controls [25]. Hence, cancer patients, compared to normal individuals, have more amount of VEGF, which was derived from leukocytes and platelets. These results suggest that non-specific inflammation induced by the tumor, irrespective of infection history, may result in leukocytosis, and that leukocytosis may contribute to increased production of angiogenic cytokines, such as VEGF-A and TGF-β1. As a result, the increased production of angiogenic cytokines may promote angiogenesis and tumor growth. If this vicious cycle can be blocked in cancer patients, tumor growth can be retarded or inhibited. Therefore, blocking this cycle could be a possible therapeutic target.

Conclusion

Serum VEGF-A, TGF-β1, and IL-β1 levels, as well as leukocyte and platelet counts were significantly associated with clinical outcomes in patients with advanced NSCLC. In addition, leukocyte and platelet counts were significantly correlated with serum VEGF-A and TGF-β1 levels. Our results suggest that the increased production of angiogenic cytokines, such as VEGF-A and TGF-β1, from leukocytes and platelets induced by tumor-associated inflammation may promote angiogenesis and tumor growth, and may result in unfavorable treatment outcomes and prognosis in patients with advanced NSCLC.

Acknowledgements

Acknowledgments

This study was supported by a grant from the Seoul National University Research Fund (04-2009-0150) and the National Research Foundation of Korea (NRF) Grant funded by the Korean Government (2010-0009563).

The authors wish to acknowledge the efforts of Ms. Hye Seon Ham and Ms. Su Jung Huh in Cancer Research Institute, Seoul National University, Seoul, Korea, and Ms. Hyun Yee Yoon in Laboratory of Protein Immunology, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea, for performing ELISA.

NOTES

Conflict of interest relevant to this article was not reported.

REFERENCES

1. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol. 2001;19:1207–1225. PMID: 11181687Article PubMed
2. Shchors K, Evan G. Tumor angiogenesis: cause or consequence of cancer? Cancer Res. 2007;67:7059–7061. PMID: 17671171Article PubMed
3. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 2006;51:143–158. PMID: 16360975Article PubMed
4. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF₁₆₅b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–7835. PMID: 15520188Article PubMed
5. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 1997;8:21–43. PMID: 9174661Article PubMed
6. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem. 1994;269:6271–6274. PMID: 8119973Article PubMed
7. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91:964–971. PMID: 11251948Article PubMed
8. Raynal S, Nocentini S, Croisy A, Lawrence DA, Jullien P. Transforming growth factor-beta1 enhances the lethal effects of DNA-damaging agents in a human lung-cancer cell line. Int J Cancer. 1997;72:356–361. PMID: 9219846Article PubMed
9. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol. 2008;29:613–616. PMID: 19115689PubMed
10. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992–1999. PMID: 15041717Article PubMed
11. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, Ivanisevic-Milovanovic O, et al. Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. Eur J Cancer. 2003;39:454–461. PMID: 12751375Article PubMed
12. Zeisler H, Tempfer C, Joura EA, Sliutz G, Koelbl H, Wagner O, et al. Serum interleukin 1 in ovarian cancer patients. Eur J Cancer. 1998;34:931–933. PMID: 9797710Article PubMed
13. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res. 1999;5:487–491. PMID: 10100697PubMed
14. Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem. 1983;258:7155–7160. PMID: 6602130Article PubMed
15. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol. 1998;16:137–161. PMID: 9597127Article PubMed
16. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314–1325. PMID: 8001745Article PubMed
17. Choi JH, Kim HC, Lim HY, Nam DK, Kim HS, Yi JW, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer. 2001;33:171–179. PMID: 11551412Article PubMed
18. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Lamberg K, Wernlund J, et al. Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients. Lung Cancer. 2002;37:57–63. PMID: 12057868Article PubMed
19. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 2005;40:90–97. PMID: 15898407Article PubMed
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216. PMID: 10655437Article PubMed
21. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61:5407–5414. PMID: 11454684PubMed
22. Ladomery MR, Harper SJ, Bates DO. Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. Cancer Lett. 2007;249:133–142. PMID: 17027147Article PubMed
23. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A. 1997;94:663–668. PMID: 9012841Article PubMed PMC
24. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80:171–175. PMID: 9684805Article PubMed
25. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000;17:149–152. PMID: 10853032Article PubMed

Fig. 1

Overall survival according to serum vascular endothelial growth factor (VEGF)-A (A) and interleukin (IL)-1β levels (B). Serum VEGF-A (A) and IL-1β (B) levels were a significant prognostic factors (p=0.0497 and p=0.047, respectively) after adjustment for smoking history, histology, and performance status.

Fig. 2

Correlation between serum vascular endothelial growth factor (VEGF)-A (A) or transforming growth factor (TGF)-β1 (B) levels and leukocyte counts. Serum VEGF-A (r=0.422, p<0.001) and TGF-β1 levels (r=0.197, p=0.020) were significantly correlated with leukocyte counts.

Fig. 3

Overall survival according to leukocyte counts. Leukocyte count was an unfavorable prognostic factor (p<0.001).

Table 1

Univariate analysis for treatment response, progression-free survival, and overall survival

Variable	No. of patients (%)	Treatment response		Progression-free survival		Overall survival
Variable	No. of patients (%)	RR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (yr)
＜60	48 (34.3)	1		1		1
≥60	92 (65.7)	1.66 (0.80-3.47)	0.699	0.93 (0.64-1.35)	0.177	1.12 (0.72-1.76)	0.605
Gender
Male	104 (74.3)	1		1		1
Female	36 (25.7)	0.73 (0.33-1.61)	0.433	0.87 (0.71-1.06)	0.169	0.61 (0.36-1.04)	0.067
Smoking history
Absent	50 (35.7)	1		1		1
Present	90 (64.3)	1.51 (0.73-3.10)	0.264	1.33 (0.92-1.92)	0.131	1.75 (1.09-2.81)	0.020
Histology
ADC	73 (52.1)	1		1		1
SCC	29 (20.7)	2.64 (1.06-6.63)	0.038	1.03 (0.65-1.62)	0.907	1.39 (0.80-2.42)	0.242
LCNEC	4 (2.9)	3.11 (0.27-36.0)	0.364	0.94 (0.30-3.02)	0.922	1.44 (0.44-4.68)	0.543
NOS	34 (24.3)	1.46 (0.63-3.38)	0.372	1.25 (0.81-1.92)	0.314	1.88 (1.15-3.10)	0.013
Stage
IIIB	24 (17.1)	1		1		1
IV	116 (82.9)	0.46 (0.19-1.15)	0.096	1.03 (0.65-1.62)	0.909	0.98 (0.57-1.70)	0.952
ECOG PS
0 or 1	118 (84.3)	1		1		1
2	22 (15.7)	0.59 (0.23-1.53)	0.278	2.68 (1.66-4.32)	＜0.001	2.48 (1.47-4.20)	0.001
Chemotherapy regimens
TP	98 (70.0)	1		1		1
Others^a)	42 (30.0)	0.56 (0.26-1.21)	0.140	0.87 (0.71-1.06)	0.163	0.99 (0.78-1.26)	0.925
VEGF-A (pg/mL)
＜1,000	99 (70.7)	1		1		1
≥1,000	41 (29.3)	1.48 (0.70-3.10)	0.302	1.07 (0.73-1.57)	0.718	1.62 (1.03-2.53)	0.035
VEGF165b (pg/mL)
＜20.0	126 (90.0)	1		1		1
≥20.0	14 (10.0)	0.59 (0.19-1.88)	0.376	0.95 (0.54-1.66)	0.857	0.72 (0.36-1.46)	0.367
TGF-β1 (pg/mL)
＜10,000	63 (45.0)	1		1		1
≥10,000	77 (55.0)	0.75 (0.38-1.50)	0.423	1.51 (1.05-2.16)	0.025	1.33 (0.86-2.06)	0.198
IL-1β (pg/mL)
＜3.00	130 (92.9)	1		1		1
≥3.00	10 (7.1)	1.45 (0.37-5.65)	0.595	2.12 (1.01-4.43)	0.046	2.38 (1.09-5.20)	0.030

RR, relative risk; CI, confidence interval; HR, hazard ratio; ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified; ECOG PS, Eastern Cooperative Oncology Group performance status; TP, taxane+platinum; VEGF, vascular endothelial growth factor; TGF, transforming growth factor; IL, interleukin. ^a)Others include gemcitabine+platinum and etoposide+platinum.

Table 2

Multivariate analysis for progression-free survival and overall survival

Cytokine	Progression-free survival		Overall survival
Cytokine	Adjusted HR^a) (95% CI)	p-value	Adjusted HR^b) (95% CI)	p-value
VEGF-A (pg/mL)
＜1,000	-		1
≥1,000	-	-	1.57 (1.00-2.47)	0.050^c)
TGF-β1 (pg/mL)
＜10,000	1		-
≥10,000	1.39 (0.97-2.00)	0.075	1	-
IL-1β (pg/mL)
＜3.00	1		1
≥3.00	1.98 (0.94-4.15)	0.070	2.24 (1.01-4.98)	0.047

HR, hazard ratio; CI, confidence interval; VEGF, vascular endothelial growth factor; TGF, transforming growth factor; IL, interleukin. ^a)Adjusted for performance status, ^b)Adjusted for smoking history, histology, and performance status, ^c)This value (0.04968...) is less than 0.05.

Table 3

Effects of baseline leukocyte or platelet counts on overall survival

Variable	Overall survival
Variable	HR (95% CI)	p-value	Adjusted HR^a) (95% CI)	p-value
Baseline leukocyte count (/mm³)
＜9,000	1		1
≥9,000	2.62 (1.68-4.07)	＜0.001	2.49 (1.58-3.94)	＜0.001
Baseline platelet count (/mm³)
＜400,000	1		1
≥400,000	1.90 (1.10-3.28)	0.021	1.56 (0.86-2.83)	0.142

HR, hazard ratio; CI, confidence interval. ^a)Adjusted for smoking history, histology, and performance status.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S.W. Tan, Enriqueta Felip, Gilberto de Castro, Benjamin J. Solomon, Alastair Greystoke, Byoung Chul Cho, Manuel Cobo, Tae Min Kim, Sandip Ganguly, Enric Carcereny, Luis Paz-Ares, Jaafar Bennouna, Marina Chiara Garassino, Michael Schenker, Sang-We K
Journal of Clinical Oncology.2024; 42(2): 192. CrossRef
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 t
Luis Paz-Ares, Yasushi Goto, Darren Wan-Teck Lim, Balazs Halmos, Byoung Chul Cho, Manuel Cobo, José Luis González Larriba, Caicun Zhou, Ingel Demedts, Akin Atmaca, Sofia Baka, Bijoyesh Mookerjee, Socorro Portella, Zewen Zhu, Jincheng Wu, David Demanse, Bh
Lung Cancer.2024; 189: 107451. CrossRef
Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer
Wanda Marini, Brooke E. Wilson, Michael Reedijk
DNA and Cell Biology.2023; 42(2): 73. CrossRef
IL-1β is involved in docetaxel chemoresistance by regulating the formation of polyploid giant cancer cells in non-small cell lung cancer
Song Zhao, Sining Xing, Lili Wang, Mingyue Ouyang, Shuo Liu, Lingyan Sun, Huiying Yu
Scientific Reports.2023;[Epub] CrossRef
Prognostic Implications of Pyroptosis-Related Gene Signatures in Lung Squamous Cell Carcinoma
Tingting Li, Huanqing Liu, Chunsheng Dong, Jun Lyu
Frontiers in Pharmacology.2022;[Epub] CrossRef
Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses
Mélanie Bruchard, Mannon Geindreau, Anaïs Perrichet, Caroline Truntzer, Elise Ballot, Romain Boidot, Cindy Racoeur, Emilie Barsac, Fanny Chalmin, Christophe Hibos, Thomas Baranek, Christophe Paget, Bernhard Ryffel, Cédric Rébé, Catherine Paul, Frédérique
Nature Immunology.2022; 23(2): 262. CrossRef
Targeting interleukin-1β and inflammation in lung cancer
Jun Zhang, Nirmal Veeramachaneni
Biomarker Research.2022;[Epub] CrossRef
Immunohistochemical Detection of Pro-Inflammatory and Anti-Inflammatory Interleukins in the Lungs of Sheep with Jaagsiekte
Emin KARAKURT, Enver BEYTUT, Serpil DAĞ, Hilmi NUHOĞLU, Ayfer YILDIZ, Emre KURTBAŞ
Turkish Journal of Veterinary Research.2022; 6(1): 9. CrossRef
Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System
Ana Belén Herrera-Campos, Esteban Zamudio-Martinez, Daniel Delgado-Bellido, Mónica Fernández-Cortés, Luis M. Montuenga, F. Javier Oliver, Angel Garcia-Diaz
Cancers.2022; 14(11): 2740. CrossRef
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology
Mark P. Lythgoe, Vinay Prasad
British Journal of Cancer.2022; 127(5): 785. CrossRef
Promotion of angiogenesis in vitro by Astragalus polysaccharide via activation of TLR4 signaling pathway
Huiqing Qiu, Liyan Zhang, Xinqi He, Yusen Wei, Miaoran Wang, Bin Ma, Dailun Hu, Zhongli Shi
Journal of Food Biochemistry.2022;[Epub] CrossRef
B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
Anqi Lin, Jianbo Fang, Quan Cheng, Zaoqu Liu, Peng Luo, Jian Zhang
Journal of Inflammation Research.2022; Volume 15: 5541. CrossRef
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer
Giuseppe Luigi Banna, Alex Friedlaender, Marco Tagliamento, Veronica Mollica, Alessio Cortellini, Sara Elena Rebuzzi, Arsela Prelaj, Abdul Rafeh Naqash, Edouard Auclin, Lucia Garetto, Laura Mezquita, Alfredo Addeo
Current Oncology Reports.2022; 24(12): 1851. CrossRef
IL-1β enhances cell viability and decreases 5-FU sensitivity in novel colon cancer cell lines derived from African American patients
Marzia Spagnardi, Jenny Paredes, Jovanny Zabaleta, Jone Garai, Tiana Reyes, Laura A. Martello, Jennie L. Williams
Frontiers in Oncology.2022;[Epub] CrossRef
Immune Resistance in Lung Adenocarcinoma
Magda Spella, Georgios T. Stathopoulos
Cancers.2021; 13(3): 384. CrossRef
The Role of Tumor Inflammatory Microenvironment in Lung Cancer
Zhaofeng Tan, Haibin Xue, Yuli Sun, Chuanlong Zhang, Yonglei Song, Yuanfu Qi
Frontiers in Pharmacology.2021;[Epub] CrossRef
Interleukin-1β and Cancer
Cédric Rébé, François Ghiringhelli
Cancers.2020; 12(7): 1791. CrossRef
Immune Cells Combined With NLRP3 Inflammasome Inhibitor Exert Better Antitumor Effect on Pancreatic Ductal Adenocarcinoma
Hailiang Liu, Yong Xu, Kai Liang, Rong Liu
Frontiers in Oncology.2020;[Epub] CrossRef
Identification of a novel subpopulation of Caspase-4 positive non-small cell lung Cancer patients
Michela Terlizzi, Chiara Colarusso, Ilaria De Rosa, Pasquale Somma, Carlo Curcio, Rita P. Aquino, Luigi Panico, Rosario Salvi, Federica Zito Marino, Gerardo Botti, Aldo Pinto, Rosalinda Sorrentino
Journal of Experimental & Clinical Cancer Research.2020;[Epub] CrossRef
A review of canakinumab and its therapeutic potential for non-small cell lung cancer
Kara M. Schenk, Joshua E. Reuss, Karin Choquette, Alexander I. Spira
Anti-Cancer Drugs.2019; 30(9): 879. CrossRef
Listeria monocytogenes Cancer Vaccines: Bridging Innate and Adaptive Immunity
Zachary T. Morrow, Zachary M. Powers, John-Demian Sauer
Current Clinical Microbiology Reports.2019; 6(4): 213. CrossRef
Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging
Ahmed Salem, Hitesh Mistry, Alison Backen, Clare Hodgson, Pek Koh, Emma Dean, Lynsey Priest, Kate Haslett, Ioannis Trigonis, Alan Jackson, Marie-Claude Asselin, Caroline Dive, Andrew Renehan, Corinne Faivre-Finn, Fiona Blackhall
Clinical Lung Cancer.2018; 19(3): 239. CrossRef
Elucidating the Role of CD84 and AHR in Modulation of LPS-Induced Cytokines Production by Cruciferous Vegetable-Derived Compounds Indole-3-Carbinol and 3,3′-Diindolylmethane
Thomas Wang, Quynhchi Pham, Young Kim
International Journal of Molecular Sciences.2018; 19(2): 339. CrossRef
IL‐1β promotes the nuclear translocaiton of S100A4 protein in gastric cancer cells MGC803 and the cell's stem‐like properties through PI3K pathway
Aiwen Yu, Yu Wang, Yue Bian, Lisha Chen, Junfu Guo, Wei Shen, Danqi Chen, Shanshan Liu, Xiuju Sun
Journal of Cellular Biochemistry.2018; 119(10): 8163. CrossRef
SNAI2 and TWIST1 in lymph node progression in early stages of NSCLC patients
Camille Emprou, Pauline Le Van Quyen, Jérémie Jégu, Nathalie Prim, Noëlle Weingertner, Eric Guérin, Erwan Pencreach, Michèle Legrain, Anne‐Claire Voegeli, Charlotte Leduc, Bertrand Mennecier, Pierre‐Emmanuel Falcoz, Anne Olland, Nicolas Santelmo, Elisabet
Cancer Medicine.2018; 7(7): 3278. CrossRef
RNA-Sequencing data supports the existence of novel VEGFA splicing events but not of VEGFAxxxb isoforms
Stephen Bridgett, Margaret Dellett, David A. Simpson
Scientific Reports.2017;[Epub] CrossRef
Cordycepin inhibits LPS-induced inflammatory responses by modulating NOD-Like Receptor Protein 3 inflammasome activation
Jing Yang, Yun-zhou Li, Phillip B. Hylemon, Lu-yong Zhang, Hui-ping Zhou
Biomedicine & Pharmacotherapy.2017; 95: 1777. CrossRef
Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Poor Prognosis in Small-cell Lung Cancer
Xu Wang, Min Liu, Lei Zhang, Kewei Ma
Archives of Medical Research.2016; 47(1): 19. CrossRef
Prediction of survival and tumor recurrence in patients undergoing surgery for pancreatic neuroendocrine neoplasms
Alexander Kaltenborn, Svenja Matzke, Moritz Kleine, Till Krech, Wolf Ramackers, Florian W. R. Vondran, Jürgen Klempnauer, Hüseyin Bektas, Harald Schrem
Journal of Surgical Oncology.2016; 113(2): 194. CrossRef
Association of CT perfusion imaging with plasma levels of TGF-β1 and VEGF in patients with NSCLC
Da-Wei Li, Bao-Zhong Wu, Yu-Sen Shi, Zhi-Qun Li, Xu-Dong Liu, Xiao-Hua Li
Asian Pacific Journal of Tropical Medicine.2016; 9(2): 177. CrossRef
Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model
Anne-Marie Baird, Steven G. Gray, Derek J. Richard, Kenneth J. O’Byrne
Scientific Reports.2016;[Epub] CrossRef
Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity
Kristian Hargadon
Journal of Clinical Medicine.2016; 5(9): 76. CrossRef
Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis
Bryant R. England, Jeremy Sokolove, William H. Robinson, Geoffrey M. Thiele, Apar K. Ganti, Harlan Sayles, Kaleb Michaud, Liron Caplan, Lisa A. Davis, Grant W. Cannon, Brian Sauer, Namrata Singh, E. Blair Solow, Andreas M. Reimold, Gail S. Kerr, Pascale S
Arthritis & Rheumatology.2016; 68(10): 2394. CrossRef
The inflammasome: an emerging therapeutic oncotarget for cancer prevention
Wang Zhiyu, Neng Wang, Qi Wang, Cheng Peng, Jin Zhang, Pengxi Liu, Aihua Ou, Shaowen Zhong, Mario D. Cordero, Yi Lin
Oncotarget.2016; 7(31): 50766. CrossRef
Elevated chronic inflammatory factors and myeloid‐derived suppressor cells indicate poor prognosis in advanced melanoma patients
Huanhuan Jiang, Christoffer Gebhardt, Ludmila Umansky, Philipp Beckhove, Torsten J. Schulze, Jochen Utikal, Viktor Umansky
International Journal of Cancer.2015; 136(10): 2352. CrossRef
The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer
Shu-Guang Liu, Shuang-Hu Yuan, Hui-Yong Wu, Jie Liu, Cheng-Suo Huang
Cell Biochemistry and Biophysics.2015; 72(1): 165. CrossRef
Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients
Bao-Hong Fu, Zhan-Zhao Fu, Wei Meng, Tao Gu, Xiao-Dong Sun, Zhi Zhang
Tumor Biology.2015; 36(8): 6477. CrossRef
Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy
Morena Fasano, Carminia Maria Della Corte, Federica Papaccio, Fortunato Ciardiello, Floriana Morgillo
Journal of Thoracic Oncology.2015; 10(8): 1133. CrossRef
The angiogenic responses induced by release of angiogenic proteins from tumor cell‐activated platelets are regulated by distinct molecular pathways
Hongyan Wu, Fangtian Fan, Zhaoguo Liu, Feng Zhang, Yuping Liu, Zhonghong Wei, Cunsi Shen, Yuzhu Cao, Aiyun Wang, Yin Lu
IUBMB Life.2015; 67(8): 626. CrossRef
Serum Calprotectin, CD26 and EGF to Establish a Panel for the Diagnosis of Lung Cancer
Sonia Blanco-Prieto, Lorena Vázquez-Iglesias, Mar Rodríguez-Girondo, Leticia Barcia-Castro, Alberto Fernández-Villar, María Isabel Botana-Rial, Francisco Javier Rodríguez-Berrocal, María Páez de la Cadena, Rossella Rota
PLOS ONE.2015; 10(5): e0127318. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

Cancer Res Treat. 2013;45(4):325-333. Published online December 31, 2013

DOI: https://doi.org/10.4143/crt.2013.45.4.325

XML Download

Figure

Related articles

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

Fig. 1 Overall survival according to serum vascular endothelial growth factor (VEGF)-A (A) and interleukin (IL)-1β levels (B). Serum VEGF-A (A) and IL-1β (B) levels were a significant prognostic factors (p=0.0497 and p=0.047, respectively) after adjustment for smoking history, histology, and performance status.

Fig. 2 Correlation between serum vascular endothelial growth factor (VEGF)-A (A) or transforming growth factor (TGF)-β1 (B) levels and leukocyte counts. Serum VEGF-A (r=0.422, p<0.001) and TGF-β1 levels (r=0.197, p=0.020) were significantly correlated with leukocyte counts.

Fig. 3 Overall survival according to leukocyte counts. Leukocyte count was an unfavorable prognostic factor (p<0.001).

Fig. 1

Fig. 2

Fig. 3

Clinical Implications of VEGF, TGF-beta1, and IL-1beta in Patients with Advanced Non-small Cell Lung Cancer

Variable	No. of patients (%)	Treatment response		Progression-free survival		Overall survival
Variable	No. of patients (%)	RR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age (yr)
＜60	48 (34.3)	1		1		1
≥60	92 (65.7)	1.66 (0.80-3.47)	0.699	0.93 (0.64-1.35)	0.177	1.12 (0.72-1.76)	0.605
Gender
Male	104 (74.3)	1		1		1
Female	36 (25.7)	0.73 (0.33-1.61)	0.433	0.87 (0.71-1.06)	0.169	0.61 (0.36-1.04)	0.067
Smoking history
Absent	50 (35.7)	1		1		1
Present	90 (64.3)	1.51 (0.73-3.10)	0.264	1.33 (0.92-1.92)	0.131	1.75 (1.09-2.81)	0.020
Histology
ADC	73 (52.1)	1		1		1
SCC	29 (20.7)	2.64 (1.06-6.63)	0.038	1.03 (0.65-1.62)	0.907	1.39 (0.80-2.42)	0.242
LCNEC	4 (2.9)	3.11 (0.27-36.0)	0.364	0.94 (0.30-3.02)	0.922	1.44 (0.44-4.68)	0.543
NOS	34 (24.3)	1.46 (0.63-3.38)	0.372	1.25 (0.81-1.92)	0.314	1.88 (1.15-3.10)	0.013
Stage
IIIB	24 (17.1)	1		1		1
IV	116 (82.9)	0.46 (0.19-1.15)	0.096	1.03 (0.65-1.62)	0.909	0.98 (0.57-1.70)	0.952
ECOG PS
0 or 1	118 (84.3)	1		1		1
2	22 (15.7)	0.59 (0.23-1.53)	0.278	2.68 (1.66-4.32)	＜0.001	2.48 (1.47-4.20)	0.001
Chemotherapy regimens
TP	98 (70.0)	1		1		1
Others^a)	42 (30.0)	0.56 (0.26-1.21)	0.140	0.87 (0.71-1.06)	0.163	0.99 (0.78-1.26)	0.925
VEGF-A (pg/mL)
＜1,000	99 (70.7)	1		1		1
≥1,000	41 (29.3)	1.48 (0.70-3.10)	0.302	1.07 (0.73-1.57)	0.718	1.62 (1.03-2.53)	0.035
VEGF165b (pg/mL)
＜20.0	126 (90.0)	1		1		1
≥20.0	14 (10.0)	0.59 (0.19-1.88)	0.376	0.95 (0.54-1.66)	0.857	0.72 (0.36-1.46)	0.367
TGF-β1 (pg/mL)
＜10,000	63 (45.0)	1		1		1
≥10,000	77 (55.0)	0.75 (0.38-1.50)	0.423	1.51 (1.05-2.16)	0.025	1.33 (0.86-2.06)	0.198
IL-1β (pg/mL)
＜3.00	130 (92.9)	1		1		1
≥3.00	10 (7.1)	1.45 (0.37-5.65)	0.595	2.12 (1.01-4.43)	0.046	2.38 (1.09-5.20)	0.030

Cytokine	Progression-free survival		Overall survival
Cytokine	Adjusted HR^a) (95% CI)	p-value	Adjusted HR^b) (95% CI)	p-value
VEGF-A (pg/mL)
＜1,000	-		1
≥1,000	-	-	1.57 (1.00-2.47)	0.050^c)
TGF-β1 (pg/mL)
＜10,000	1		-
≥10,000	1.39 (0.97-2.00)	0.075	1	-
IL-1β (pg/mL)
＜3.00	1		1
≥3.00	1.98 (0.94-4.15)	0.070	2.24 (1.01-4.98)	0.047

Variable	Overall survival
Variable	HR (95% CI)	p-value	Adjusted HR^a) (95% CI)	p-value
Baseline leukocyte count (/mm³)
＜9,000	1		1
≥9,000	2.62 (1.68-4.07)	＜0.001	2.49 (1.58-3.94)	＜0.001
Baseline platelet count (/mm³)
＜400,000	1		1
≥400,000	1.90 (1.10-3.28)	0.021	1.56 (0.86-2.83)	0.142

Table 1 Univariate analysis for treatment response, progression-free survival, and overall survival

Table 2 Multivariate analysis for progression-free survival and overall survival

Table 3 Effects of baseline leukocyte or platelet counts on overall survival

HR, hazard ratio; CI, confidence interval. ^a)Adjusted for smoking history, histology, and performance status.